OK, what do you think would be appropriate at this stage? $, shares, oppies?
There will be a lot of CRs to come, regardless of what they pay themselves. Clinical trials costs $m, the more they progress the more they have to raise. Any pay day will be probably after a successful Ph2, still a few years away. Unless someone wants to buy it out, but again, needs fantastic data to achieve that.
GLTA
CEO Renumeration, page-5
-
- There are more pages in this discussion • 43 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IVX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $13.53M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.2¢ | $7.928K | 3.768M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 48 | 43978864 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 7811467 | 20 |
View Market Depth
| Last trade - 15.59pm 18/10/2024 (20 minute delay) ? |
| IVX (ASX) Chart |